Log in

Relevant bibliographies by topics / Intranasal ES-Ketamine

Contents

Journal articles
Dissertations / Theses

Academic literature on the topic 'Intranasal ES-Ketamine'

Author: Grafiati

Published: 14 March 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Intranasal ES-Ketamine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Intranasal ES-Ketamine"

1

Alario, Alexandra A., and Mark J. Niciu. "(Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy." Chronic Stress 6 (January 2022): 247054702211280. http://dx.doi.org/10.1177/24705470221128017.

Full text

Abstract:

Suicidal ideation and behavior are among the most severe psychiatric presentations, warranting emergency room visits and psychiatric admission for higher levels of care. In the United States, suicide rates continue to climb, especially in younger patients, and the continued psychosocial stressors of the COVID-19 pandemic may further exacerbate this crisis. Suicidal ideation and behavior are core features of a major depressive episode, but there are limited treatment options to rapidly redress these life-threatening symptoms. Racemic ketamine and its S-enantiomer, esketamine, are N-methyl-D-asp

APA, Harvard, Vancouver, ISO, and other styles

2

Hauser, Johannes, Jan Sarlon, Timur Liwinski, Annette B. Brühl, and Undine E. Lang. "Listening to music during intranasal (es)ketamine therapy in patients with treatment-resistant depression correlates with better tolerability and reduced anxiety." Frontiers in Psychiatry 15 (January 23, 2024). http://dx.doi.org/10.3389/fpsyt.2024.1327598.

Full text

Abstract:

BackgroundAlthough the effectiveness of (es)ketamine for therapy-resistant depression (TRD) has been established, potential treatment-limiting factors include side effects like dissociation, anxiety, or elevated blood pressure. Music can reduce stress and negative emotions as anxiety. This study aimed to investigate the impact of listening to music during intranasal (es)ketamine administration on both tolerability and efficacy.MethodsRecords of 494 sessions (of 37 patients) with intranasal (es)ketamine administration, each containing data of blood pressure measurements, DSS-IV (dissociation sy

APA, Harvard, Vancouver, ISO, and other styles

3

Keeler, Johanna Louise, Janet Treasure, Hubertus Himmerich, Madeline Brendle, Claire Moore, and Reid Robison. "Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa." Frontiers in Psychiatry 14 (May 15, 2023). http://dx.doi.org/10.3389/fpsyt.2023.1181447.

Full text

Abstract:

IntroductionA comorbid diagnosis of a depressive disorder is a negative prognostic factor for individuals with AN, and novel treatments are needed to target depressive symptoms in this population. One emerging promising treatment for depressive disorders is ketamine, although there is less research investigating the use of ketamine for alleviating depression in people with AN.Case reportThis study reports on four patients with a lifetime diagnosis of AN and a comorbid diagnosis of major depressive disorder who received either intramuscular ketamine (n = 2) or intranasal esketamine (n = 2) trea

APA, Harvard, Vancouver, ISO, and other styles

4

Veraart, Jolien KE, Sanne Y. Smith-Apeldoorn, Annemarie van der Meij, Jan Spijker, Robert A. Schoevers, and Jeanine Kamphuis. "Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program." Journal of Psychopharmacology, April 25, 2025. https://doi.org/10.1177/02698811251332831.

Full text

Abstract:

Background: Oral esketamine for patients with treatment-resistant depression (TRD) could offer certain advantages over other routes, such as intravenous or intranasal, but it has not been systematically studied in a real-world setting. Aims: Here we present results from a relatively large naturalistic study to evaluate the effectiveness, tolerability, and safety of oral esketamine in patients with TRD. Methods: One hundred eighty-five adults with severe TRD (average of 8.1 antidepressant trials plus electroconvulsive therapy in 63% without beneficial outcome) received oral esketamine treatment

APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Intranasal ES-Ketamine"

1

Cuomo, Alessandro. ""TREATMENT-RESISTANT DEPRESSION" AND USE OF INTRAVENOUS KETAMINE AND INTRANASAL ES-KETAMINE." Doctoral thesis, Università di Siena, 2021. http://hdl.handle.net/11365/1148507.

Full text

Abstract:

Treatment-Resistant Depression (TRD) is defined as major depression characterized by the unsatisfactory response of two or more antidepressant therapies (adequate for dosage and duration), associated with a high incidence of comorbidities, with more marked impairment of functioning socio-occupational and greater risks of relapse, recurrence and suicidality. The high incidence of TRD has advanced scientific research towards the study of molecules with antidepressant action and with different mechanisms of action than those based on the monoaminergic theory. Ketamine is one of these molecules. A

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!